ARID1A and uterine carcinoma: Guan et al compared ARID1A IHC and mutational status in uterine carcinomas using the polyclonal HPA005456 antibody (targeting amino acids 1266–1370), with negativity defined as absence of nuclear staining, and identified that only 50% (5/10) of cases with deleterious mutations showed complete lack of ARID1A expression.